Rizvi, N. A., Pao, W., Chaft, J. E., Ladanyi, M., Miller, V. A., Krug, L. M., . . . Kris, M. G. (2011). Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Rizvi, Naiyer A., et al. Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib With the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene. 2011.

Rizvi, Naiyer A., et al. Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib With the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene. 2011.